Treatment options for prehypertension

• Published in: Current opinion in nephrology and hypertension Vol. 16; no. 3; pp. 250 - 255
• Main Author: Nesbitt, Shawna D
• Format: Journal Article
• Language: English
• Published: England Lippincott Williams & Wilkins, Inc 01-05-2007
• Subjects: Angiotensin II Type 1 Receptor Blockers - pharmacology; Angiotensin II Type 1 Receptor Blockers - therapeutic use; Antihypertensive Agents - pharmacology; Antihypertensive Agents - therapeutic use; Benzimidazoles - therapeutic use; Blood Pressure - drug effects; Diet; Disease Progression; Exercise; Humans; Hypertension - epidemiology; Hypertension - physiopathology; Hypertension - prevention & control; Incidence; Life Style; Practice Guidelines as Topic; Tetrazoles - therapeutic use
• ISSN: 1062-4821; 1473-6543
• DOI: 10.1097/MNH.0b013e3280c8eebe

PURPOSE OF REVIEWPrehypertension is a recognized stage of blood pressure but treatment standards have not yet been established. This review will focus on the treatment considerations in prehypertension.
RECENT FINDINGSPrevious approaches to prehypertensive blood pressure have focused on the role of nonpharmacologic modalities alone. The recently published Trial of Preventing Hypertension (TROPHY) is the first study of pharmacologic intervention in this category of blood pressure.
SUMMARYTROPHY forged new territory in the area of pharmacologic treatment for prehypertension. The safety and tolerability of the angiotensin receptor blocker treatment in the trial offer a new option to clinicians attempting to avoid the ravages of hypertension in the patients they treat. Furthermore the stage is properly set for additional research in treatments for prehypertension.